All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Completed, but no date, and reported results | 2004-004974-94 | Efficacy and safety of tafluprost 0.0015% eye drops as adjunctive therapy with timolol 0.5% eye drops. A randomised, placebo-controlled, phase III study in patients with open-angle glaucoma or ocular ... | bad-data | |
| Reported results | 2005-002574-29 | Pharmacodynamics of tafluprost 0.0015% eye drops: a comparison between the preserved and unpreserved formulation in patients with open-angle glaucoma or ocular hypertension. | 2006-04-05 | due-trials |
| Exempt, with results | 2006-001156-12 | Corneal penetration of timolol into the human aqueous humor after administration of 0.1% Timosan eye gel or 0.5% timolol eye drops | 2006-11-28 | not-yet-due |
| Reported results | 2007-004872-37 | A phase IIIb study on the changes in ocular signs, symptoms and conjunctival inflammatory markers in patients with ocular hypertension or open-angle glaucoma switched from preserved latanoprost 0.005%... | 2008-07-11 | due-trials |
| Completed, but no date, and reported results | 2010-020746-98 | An open-label phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from preserved travoprost 0.004% eye drops to preservative... | bad-data | |
| Reported results | 2010-022965-82 | A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to tho... | 2012-09-24 | due-trials |
| Reported results | 2010-022984-36 | A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to tho... | 2012-05-03 | due-trials |
| Completed, but no date, and reported results | 2010-023627-14 | Cross-sectional study to investigate the occurence and severity of signs and symptoms of ocular surface disease in patients with ongoing chronic topical treatment for glaucoma or ocular hypertension. | bad-data | |
| Reported results | 2011-001595-19 | A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE- 109 (three doses) for the Treatment of active, Non-Infec... | 2016-09-30 | due-trials |
| Reported results | 2013-004302-26 | A phase I study to evaluate the pharmacokinetics, safety and tolerability of preservative free tafluprost ophthalmic solution (0.0015%) in pediatric patients diagnosed with glaucoma or ocular hyperten... | 2017-06-05 | due-trials |
| Reported results | 2014-004042-96 | A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects with Non-Infectious Uveitis of the Posterior Se... | 2017-11-01 | due-trials |
| Reported results | 2014-005273-37 | A phase IV study on changes in ocular signs and symptoms in patients with with ocular hypertension or open-angle glaucoma switched from Ganfort¿ eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom¿... | 2016-05-25 | due-trials |
| Completed, but no date, and reported results | 2016-003497-40 | A PHASE IV, PROSPECTIVE, OPEN-LABEL, MULTICENTRE, SINGLE ARM, 3-MONTH PROOF OF CONCEPT STUDY TO ASSESS THE EFFECT OF IKERVIS® 1MG/ML (CICLOSPORIN) EYE DROPS ADMINISTERED ONCE DAILY ON THE QUALITY OF V... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-002660-41 | A Phase IIIb, prospective, interventional, multicentre, three-year study to explore the long-term evolution of sign and symptoms, and occurrence of complications in Dry Eye Disease patients with sever... | 2023-07-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-004262-95 | Phase III, Multinational, Multicenter, Investigator-Masked, Randomised, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocul... | 2022-10-26 | bad-data |
| Reported results Terminated | 2019-003638-18 | LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 µg DE-109 for the Treatment of Active, Non-Infec... | 2022-05-11 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2020-004836-93 | An Exploratory Study to Assess the 24-hour Intraocular Pressure (IOP) Lowering Characteristics, Duration of Action and Safety of DE-126 ophthalmic solution 0.002% versus Latanoprost ophthalmic solutio... | 2023-01-09 | bad-data |
| Ongoing | 2022-000174-25 | A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehicle... | not-yet-due |